Alecnib 150 mg (Alectinib) 56 tab

Alecnib 150 mg (Alectinib) (Alecensa)

Active ingredient: Alectinib 150 mg per capsule
Brand: Alecnib (Everest Pharmaceuticals Ltd., Bangladesh)
Therapeutic Class: Tyrosine Kinase Inhibitor, ALK inhibitor

Indications

Alecnib is indicated for treatment of adult patients with ALK-positive non-small cell lung cancer (NSCLC):

• As first-line therapy in advanced ALK-positive NSCLC.
• For patients who have progressed on or are intolerant to crizotinib.

Mechanism of Action

Alectinib inhibits the activity of the anaplastic lymphoma kinase (ALK) fusion proteins and RET tyrosine kinases, downstream signaling (e.g. STAT3, PI3K/AKT), leading to reduced tumor cell growth and survival, including in some brain metastases.

Dosage & Administration

• Usual dose: 600 mg twice daily with food (total daily dose 1200 mg)
• For patients with severe hepatic impairment (Child-Pugh C): reduce to 450 mg twice daily (900 mg/day)
• Continue treatment until disease progression or unacceptable toxicity.

Common Side Effects

Some of the more frequent adverse reactions include:

• Myalgia (muscle pain)
• Constipation
• Nausea
• Increased bilirubin levels
• Anemia
• Skin rash
• Peripheral edema
• Fatigue

Precautions and Contraindications

• Do not use in patients with known hypersensitivity to alectinib or any excipients.
• Use with caution in patients with hepatic impairment; dose adjustments required for severe hepatic dysfunction.
• Monitor liver enzymes (ALT/AST) and bilirubin during treatment.